Creating a new injectable antibiotic for serious drug-resistant infections
Official title: Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive Infections
Funded at Aimmax Therapeutics, INC. · NIH-10837145 · Data updated 2026-11-12
This study is testing a new antibiotic called AMX-2005 to see if it can help treat serious infections caused by tough bacteria like MRSA and VRE, giving hope to patients who need better options when current treatments don’t work.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aimmax Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | May 4, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $306,953 |
| NIH project number | 5R43AI174384-02 |
| Project ID | NIH-10837145 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from infections caused by multidrug-resistant gram-positive bacteria.
✕Less likely to help
Patients with infections caused by bacteria that are not gram-positive or those who do not have antibiotic-resistant infections may not benefit from this research.
What this research studies
This research focuses on developing a novel antibiotic, AMX-2005, aimed at treating serious infections caused by multidrug-resistant gram-positive bacteria, such as MRSA and VRE. The approach involves testing the antibiotic's effectiveness in laboratory settings and in animal models to ensure it can effectively kill these resistant bacteria. By targeting pathogens that have become resistant to existing treatments, this research aims to provide new therapeutic options for patients suffering from severe infections.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients with serious infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Previous research has shown success in developing new antibiotics targeting resistant bacteria, indicating a promising avenue for this novel approach.
Where this research is happening
-
Aimmax Therapeutics, INC.
Durham, United States Active
Researchers
- Principal investigator: Keedy, Kara S — Aimmax Therapeutics, INC.
- Study coordinator: Keedy, Kara S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.